Lakewood-Amedex Biotherapeutics reports positive preclinical data
Lakewood-Amedex Biotherapeutics Inc said it has positive preclinical data for Bisphosphocin® compounds in urinary tract and pulmonary infection indications.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lakewood-Amedex Biotherapeutics reports positive preclinical data
Lakewood-Amedex Biotherapeutics announced positive preclinical data for urinary tract and pulmonary infection indications using bisphosphocin compounds, per a Dow Jones Newswires item.
Lakewood-Amedex reports positive preclinical Bisphosphocin data
Lakewood-Amedex Biotherapeutics said Bisphosphocin compounds showed positive preclinical results in urinary tract and pulmonary infection animal models. In one rodent UTI model, Nu-8 produced up to 97% inhibition of E. coli growth versus no effect in a vehicle control group.
Lakewood-Amedex Biotherapeutics reports positive preclinical data
Lakewood-Amedex Biotherapeutics (LABT) announced positive preclinical data in urinary tract and pulmonary infection indications using Bisphosphocin® compounds.